In:
JNCI: Journal of the National Cancer Institute, Oxford University Press (OUP), ( 2023-09-15)
Abstract:
Prostate cancer (PC) is the most diagnosed cancer in African American men (AAM), yet PC screening regimens in this group are poorly guided by existing evidence, given underrepresentation of AAM in prostate cancer screening trials. It is critical to optimize PC screening and early detection in this high-risk group since underdiagnosis may lead to later stage cancers at diagnosis and higher mortality while overdiagnosis may lead to unnecessary treatment. Methods We performed a review of the literature related to PC screening and early detection specific to AAM to summarize the existing evidence available to guide healthcare practice. Results Limited evidence from observational and modeling studies suggests that AAM should be screened for PC. Consideration should be given to initiating screening AAM at younger ages (eg, 45-50 years) and at more frequent intervals relative to other racial groups in the U.S. Screening intervals may be optimized through use of a baseline PSA measurement in midlife. Lastly, no evidence indicated that AAM would benefit from screening beyond age 75 years, and AAM may experience higher rates of overdiagnosis at older ages. Conclusions The evidence base for PC screening in AAM is limited by the lack of large, randomized studies. Our literature search supported the need for AAM to be screened for PC, for initiating screening at younger ages (45-50 years) and perhaps at more frequent intervals among AAM relative to men of other racial groups in the U.S.
Type of Medium:
Online Resource
ISSN:
0027-8874
,
1460-2105
DOI:
10.1093/jnci/djad193
Language:
English
Publisher:
Oxford University Press (OUP)
Publication Date:
2023
detail.hit.zdb_id:
2992-0
detail.hit.zdb_id:
1465951-7
Permalink